Recent Quotes (30 days)

You have no recent quotes
chg | %

Compass Biotechnologies, Inc.  

(Public, OTCMKTS:COBI)   Watch this stock  
Find more results for OTC:CPBM
0.0002
0.0000 (0.00%)
Sep 30 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/1.05M
Mkt cap 105,070.00
P/E     -
Div/yield     -
EPS -0.01
Shares 327.63M
Beta -13.02
Inst. own     -

Key stats and ratios

Q3 (Jul '12) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -18.11% -124.06%
Return on average equity - -
Employees 2 -
CDP Score - -

Address

Suite 200, 4105 N. 20th Street,
PHOENIX, AZ 85106
United States - Map
+1-480-2588671 (Phone)
+1-780-6697633 (Fax)

Description

Compass Biotechnologies Inc. is a biotechnology research and development company. The Company focuses on the development and commercialization of generic, bio-similar and bio-better drug products.The Company is a pharmaceutical company focused on hepatitis anti-viral drugs and prophylactic vaccines, recombinant protein therapeutics called biobetters, and cytokine reagents. In February 2011, the Company out-licensed the VLP vaccine project and the two Hepatitis C generic drugs to its wholly owned Canadian subsidiary C-Pharma Inc formerly Cyplasin Oncoscience Inc. C-Pharma is focused on the development of the Hepatitis C products and also to expand the pipeline of products to develop a Hepatitis franchise. During the fiscal year ended January 31, 2012, the Company had not generated any revenues from its technologies.

Officers and directors

Garth Likes Chairman of the Board
Joseph Sinkule Chief Executive Officer, President, Chief Operating Officer, Director